Thus, OX40L/PPT treatment resulted in tumor growth reduction and significant survival enhancement in CT26 subcutaneous colon cancer model, and led to protective immunity against CT26gfp colon cancer cells. The gene discussed is TNFSF4; the disease is neoplasm.